Skip to main content

argenx SE provided updated trial data

argenx SE (Nasdaq: ARGX) provided an update to its Phase 1/2 clinical trial of ARGX-110 in cutaneous T-cell lymphoma and announced a proposed public offering of $150 million American Depositary Shares. Shares of the biopharmaceutical leaped $24.02 to close at $54.47.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.